Stefan Rose-John

List of Publications by Year
in descending order

568 papers	51,314 citations	1368 108 h-index	2274 200 g-index
616 all docs	616 docs citations	616 times ranked	53782 citing authors

#	Article	IF	Citations
1	The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 878-888.	1.9	2,433
2	IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells andÂDevelopment of Colitis-Associated Cancer. Cancer Cell, 2009, 15, 103-113.	7.7	1,851
3	Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nature Medicine, 2000, 6, 583-588.	15.2	1,197
4	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	7.7	811
5	IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6. International Journal of Biological Sciences, 2012, 8, 1237-1247.	2.6	764
6	Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer. Cancer Cell, 2011, 19, 456-469.	7.7	754
7	IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation. Immunity, 2001, 14, 705-714.	6.6	718
8	TGF-Î² Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling. Immunity, 2004, 21, 491-501.	6.6	700
9	The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood, 2003, 102, 1186-1195.	0.6	624
10	IL-6 pathway in the liver: From physiopathology to therapy. Journal of Hepatology, 2016, 64, 1403-1415.	1.8	606
11	Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation, 2011, 121, 3375-3383.	3.9	581
12	Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. Journal of Leukocyte Biology, 2006, 80, 227-236.	1.5	552
13	Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. FEBS Journal, 2001, 268, 160-167.	0.2	544
14	A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metabolism, 2014, 20, 433-447.	7.2	535
15	A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nature Biotechnology, 1997, 15, 142-145.	9.4	504
16	Interleukin-6 Family Cytokines. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028415.	2.3	501
17	Transcriptional profiling identifies Id2 function in dendritic cell development. Nature Immunology, 2003, 4, 380-386.	7.0	469
18	The soluble interleukin-6 receptor is generated by shedding. European Journal of Immunology, 1993, 23, 473-480.	1.6	458

#	Article	IF	Citations
19	ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends in Immunology, 2011, 32, 380-387.	2.9	443
20	Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine, 2014, 70, 11-20.	1.4	443
21	Interleukin-6: designing specific therapeutics for a complex cytokine. Nature Reviews Drug Discovery, 2018, 17, 395-412.	21.5	440
22	Interleukin-6: Biology, signaling and strategies of blockade. Cytokine and Growth Factor Reviews, 2015, 26, 475-487.	3.2	396
23	Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors. Journal of Biological Chemistry, 1996, 271, 11376-11382.	1.6	371
24	The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-Î³ and TNF-Î± and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10. Journal of Immunology, 2004, 172, 6362-6372.	0.4	369
25	The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Current Opinion in Immunology, 2015, 34, 75-82.	2.4	345
26	The role of interleukin-6 signaling in nervous tissue. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1218-1227.	1.9	335
27	Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE). Journal of Biological Chemistry, 2003, 278, 38829-38839.	1.6	332
28	The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opinion on Therapeutic Targets, 2007, 11, 613-624.	1.5	314
29	Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine and Growth Factor Reviews, 2012, 23, 85-97.	3.2	311
30	Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nature Immunology, 2017, 18, 74-85.	7.0	311
31	Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 2009, 50, 1773-1782.	3.6	309
32	G Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment during Intestinal Inflammation. Journal of Immunology, 2009, 183, 7514-7522.	0.4	308
33	The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nature Reviews Rheumatology, 2017, 13, 399-409.	3.5	303
34	IL-6/IL-6R Axis Plays a Critical Role in Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 1106-1115.	3.0	301
35	Sympathetic neurons can produce and respond to interleukin 6. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3251-3256.	3.3	297
36	Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. Journal of Experimental Medicine, 2015, 212, 1641-1662.	4.2	293

#	Article	IF	Citations
37	Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner. Cell, 2020, 180, 833-846.e16.	13.5	292
38	The IL-6R Î± chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. Journal of Clinical Investigation, 2005, 115, 313-325.	3.9	292
39	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Journal of Experimental Medicine, 2010, 207, 1617-1624.	4.2	286
40	Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood, 2007, 110, 1748-1755.	0.6	281
41	Maintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent. Stem Cells, 2004, 22, 522-530.	1.4	278
42	IL-6 biology: implications for clinical targeting in rheumatic disease. Nature Reviews Rheumatology, 2014, 10, 720-727.	3.5	259
43	The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.. Journal of Experimental Medicine, 1996, 183, 1399-1406.	4.2	257
44	RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovascular Research, 2014, 103, 206-216.	1.8	257
45	CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nature Medicine, 2006, 12, 541-548.	15.2	250
46	IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3. Journal of Immunology, 2011, 186, 1199-1208.	0.4	250
47	Interleukin-6 Trans-Signalling in Chronic Inflammation and Cancer. Scandinavian Journal of Immunology, 2006, 63, 321-329.	1.3	249
48	Structure of an Extracellular gp130 Cytokine Receptor Signaling Complex. Science, 2001, 291, 2150-2155.	6.0	248
49	The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer. European Journal of Cell Biology, 2011, 90, 484-494.	1.6	248
50	Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. Seminars in Immunology, 2014, 26, 2-12.	2.7	246
51	The shedding protease ADAM17: Physiology and pathophysiology. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2059-2070.	1.9	246
52	Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis. Blood, 1998, 92, 3495-3504.	0.6	243
53	IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. Journal of Clinical Investigation, 2013, 123, 1019-1031.	3.9	238
54	Interplay between IFN-Î³ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. Journal of Clinical Investigation, 2003, 112, 598-607.	3.9	229

#	Article	IF	Citations
55	Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood, 2008, 111, 1021-1028.	0.6	228
56	The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1592, 251-263.	1.9	226
57	Interleukin-6 and its receptor: from bench to bedside. Medical Microbiology and Immunology, 2006, 195, 173-183.	2.6	225
58	Review:IL-6 Transsignaling: TheIn VivoConsequences. Journal of Interferon and Cytokine Research, 2005, 25, 241-253.	0.5	222
59	Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130. Journal of Immunology, 2003, 171, 3202-3209.	0.4	219
60	L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin/Î³-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite Outgrowth. Molecular and Cellular Biology, 2005, 25, 9040-9053.	1.1	212
61	Loss of P53 Function Activates JAK2â€“STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, andÂGemcitabine Resistance in Mice and Is Associated WithÂPatient Survival. Gastroenterology, 2016, 151, 180-193.e12.	0.6	211
62	Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25â^' T Cells. Journal of Immunology, 2007, 179, 2041-2045.	0.4	209
63	Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance. Cell Metabolism, 2015, 21, 403-416.	7.2	208
64	Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages. Gastroenterology, 2011, 141, 2026-2038.	0.6	206
65	IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer. Cell Cycle, 2005, 4, 220-223.	1.3	204
66	Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 281-290.	1.1	203
67	Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nature Immunology, 2006, 7, 1299-1308.	7.0	197
68	Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Solubleâ€“IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model. Journal of Immunology, 2010, 184, 1543-1551.	0.4	197
69	Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2658-2668.	1.1	196
70	Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain. Journal of Neuroscience, 2014, 34, 2503-2513.	1.7	194
71	Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends in Biotechnology, 2010, 28, 37-45.	4.9	193
72	IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. Journal of Clinical Investigation, 2011, 121, 3846-3859.	3.9	187

#	Article	IF	Citations
73	Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis. Journal of Immunology, 2009, 182, 613-622.	0.4	185
74	IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer. Cancer Research, 2011, 71, 424-434.	0.4	184
75	STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut, 2020, 69, 1269-1282.	6.1	181
76	IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Reports, 2017, 19, 267-280.	2.9	175
77	Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding. Journal of Biological Chemistry, 2011, 286, 14804-14811.	1.6	174
78	The IL-6â€“gp130â€“STAT3 pathway in hepatocytes triggers liver protection in T cellâ€–mediated liver injury. Journal of Clinical Investigation, 2005, 115, 860-869.	3.9	172
79	The IL-6R Î± chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. Journal of Clinical Investigation, 2005, 115, 313-325.	3.9	170
80	Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cellâ€“Activating Receptor NKp30. Cancer Research, 2014, 74, 3429-3440.	0.4	169
81	A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology, 2010, 11, 1119-1126.	7.0	168
82	Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6â€“sIL-6R Double Transgenic Mice. Journal of Experimental Medicine, 1997, 185, 755-766.	4.2	167
83	Loss of CD4+ T Cell IL-6R Expression during Inflammation Underlines a Role for IL-6TransSignaling in the Local Maintenance of Th17 Cells. Journal of Immunology, 2010, 184, 2130-2139.	0.4	166
84	Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*. Critical Care Medicine, 2011, 39, 1407-1413.	0.4	163
85	VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Journal of Experimental Medicine, 2010, 207, 2855-2868.	4.2	152
86	Shedding of interleukin-6 receptor and tumor necrosis factorâ€ƒÎ±. FEBS Journal, 2000, 267, 2624-2631.	0.2	149
87	Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. , 1999, 26, 191-200.		148
88	Interleukin-6 and Neural Stem Cells: More Than Gliogenesis. Molecular Biology of the Cell, 2009, 20, 188-199.	0.9	145
89	IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling. Journal of Immunology, 2013, 190, 703-711.	0.4	140
90	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136

#	Article	IF	Citations
91	Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor. Journal of Biological Chemistry, 2011, 286, 42959-42970.	1.6	133
92	Molecular cloning of mouse protein kinase C (PKC) cDNA from Swiss 3T3 fibroblasts. Gene, 1988, 74, 465-471.	1.0	132
93	Genetic partitioning of interleukinâ€6 signalling in mice dissociates Stat3 from Smad3â€mediated lung fibrosis. EMBO Molecular Medicine, 2012, 4, 939-951.	3.3	128
94	Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1757-1762.	3.3	127
95	A Key Role for gp130 Expressed on Peripheral Sensory Nerves in Pathological Pain. Journal of Neuroscience, 2009, 29, 13473-13483.	1.7	125
96	The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation. Clinical Pharmacology and Therapeutics, 2017, 102, 591-598.	2.3	125
97	ILâ€6 transâ€signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology, 2017, 65, 89-103.	3.6	125
98	Signaling of Human Ciliary Neurotrophic Factor (CNTF) Revisited. Journal of Biological Chemistry, 2003, 278, 9528-9535.	1.6	123
99	Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain, 2005, 128, 1634-1641.	3.7	123
100	Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO Journal, 1998, 17, 5588-5597.	3.5	121
101	TGF-Î²1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. American Journal of Physiology - Renal Physiology, 1999, 276, G1059-G1068.	1.6	120
102	Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respiratory Medicine,the, 2021, 9, 643-654.	5.2	120
103	Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology, 2021, 160, 2354-2366.e11.	0.6	120
104	The hepatic interleukin-6 receptor Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Letters, 1992, 306, 219-222.	1.3	119
105	The Interleukin-6 Cytokine System Regulates Epidermal Permeability Barrier Homeostasis. Journal of Investigative Dermatology, 2004, 123, 124-131.	0.3	118
106	The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1485-1494.	1.8	118
107	Classic Interleukin-6 Receptor Signaling and Interleukin-6 trans-Signaling Differentially Control Angiotensin II-Dependent Hypertension, Cardiac Signal Transducer and Activator of Transcription-3 Activation, and Vascular Hypertrophy in Vivo. American Journal of Pathology, 2007, 171, 315-325.	1.9	116
108	Differentially regulated GPVI ectodomain shedding by multiple plateletâ€“expressed proteinases. Blood, 2010, 116, 3347-3355.	0.6	116

#	Article	IF	Citations
109	Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. European Journal of Neuroscience, 1999, 11, 2995-3004.	1.2	115
110	IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. Journal of Lipid Research, 2015, 56, 1034-1042.	2.0	114
111	Role of interleukinâ€6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB Journal, 2003, 17, 1-20.	0.2	113
112	The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprinÂÎ² and ADAM10. Cellular and Molecular Life Sciences, 2013, 70, 309-333.	2.4	112
113	An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer. Journal of Biological Chemistry, 2013, 288, 4346-4354.	1.6	112
114	Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles. Journal of Biological Chemistry, 2015, 290, 26059-26071.	1.6	112
115	HHV-8â€“encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood, 2012, 119, 5173-5181.	0.6	110
116	Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochemical and Biophysical Research Communications, 1992, 189, 794-800.	1.0	109
117	The family of the IL-6-Type cytokines: Specificity and promiscuity of the receptor complexes. , 1997, 27, 96-109.		109
118	Enzymatically Degraded, Nonoxidized LDL Induces Human Vascular Smooth Muscle Cell Activation, Foam Cell Transformation, and Proliferation. Circulation, 2000, 101, 1799-1805.	1.6	109
119	Liver regeneration induced by a designer human ILâ€6/ sILâ€6R fusion protein reverses severe hepatocellular injury. FASEB Journal, 2000, 14, 1979-1987.	0.2	109
120	Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. Journal of Comparative Neurology, 2002, 454, 213-228.	0.9	107
121	STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut, 2006, 55, 1263-1269.	6.1	107
122	Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Letters, 1993, 332, 174-178.	1.3	104
123	Proteolytic Cleavage Governs Interleukin-11 Trans-signaling. Cell Reports, 2016, 14, 1761-1773.	2.9	104
124	Studies on the structure and regulation of the human hepatic interleukin-6 receptor. FEBS Journal, 1990, 190, 79-83.	0.2	103
125	Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7882-7887.	3.3	102
126	Radiation-Induced Loss of Salivary Gland Function Is Driven by Cellular Senescence and Prevented by IL6 Modulation. Cancer Research, 2016, 76, 1170-1180.	0.4	102

#	Article	IF	Citations
127	Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis. Journal of Scleroderma and Related Disorders, 2017, 2, S1-S5.	1.0	102
128	Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Experimental Hematology, 1999, 27, 817-825.	0.2	101
129	Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine and Growth Factor Reviews, 2006, 17, 451-461.	3.2	100
130	The transcription factor NFATc2 controls IL-6â€“dependent T cell activation in experimental colitis. Journal of Experimental Medicine, 2008, 205, 2099-2110.	4.2	99
131	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	6.0	99
132	Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation. PLoS Biology, 2017, 15, e2000080.	2.6	99
133	IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6. Journal of Immunology, 2000, 164, 4672-4677.	0.4	98
134	Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25â^' and CD25high regulatory T cells. International Immunology, 2006, 18, 555-563.	1.8	97
135	ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight, 2016, 1, .	2.3	96
136	Inhibition of T Cell Apoptosis in the Aqueous Humor of Patients with Uveitis by IL-6/Soluble IL-6 Receptor trans-Signaling. Journal of Immunology, 2004, 173, 5290-5297.	0.4	95
137	Soluble tumor necrosis factor (TNF) receptorâ€1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factorâ€β1. FASEB Journal, 2005, 19, 91-93.	0.2	95
138	IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions. Journal of Investigative Dermatology, 2014, 134, 728-735.	0.3	95
139	Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis. Blood, 1998, 92, 3495-3504.	0.6	95
140	Sleep enhances ILâ€6 transâ€signaling in humans. FASEB Journal, 2006, 20, 2174-2176.	0.2	94
141	Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology, 2007, 45, 486-494.	3.6	94
142	Inhibition of ILâ€6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. International Journal of Cancer, 2015, 137, 1035-1046.	2.3	94
143	The transcription factor IFN regulatory factorâ€“4 controls experimental colitis in mice via T cellâ€“derived IL-6. Journal of Clinical Investigation, 2008, 118, 2415-26.	3.9	94
144	IL-6 trans-Signaling. Immunity, 2004, 20, 2-4.	6.6	93

#	Article	IF	Citations
145	A Disintegrin and Metalloprotease (ADAM) 10 and ADAM17 Are Major Sheddases of T Cell Immunoglobulin and Mucin Domain 3 (Tim-3). Journal of Biological Chemistry, 2013, 288, 34529-34544.	1.6	93
146	Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 371-380.	0.6	92
147	IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. Cancer Research, 2016, 76, 866-876.	0.4	92
148	Receptor Recognition Sites of Cytokines Are Organized as Exchangeable Modules. Journal of Biological Chemistry, 1999, 274, 11859-11867.	1.6	91
149	Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells. Journal of Biological Chemistry, 2007, 282, 3014-3026.	1.6	90
150	The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. Journal of Clinical Investigation, 2005, 115, 860-9.	3.9	90
151	Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis and Rheumatism, 2006, 54, 1662-1672.	6.7	89
152	ELPylated antiâ€human TNF therapeutic singleâ€domain antibodies for prevention of lethal septic shock. Plant Biotechnology Journal, 2011, 9, 22-31.	4.1	89
153	Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. , 1999, 55, 411-422.		88
154	Activation of gp 130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. European Journal of Neuroscience, 1997, 9, 2765-2773.	1.2	86
155	Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mice. American Journal of Pathology, 1998, 153, 639-648.	1.9	86
156	Mind-Body Medicine: Stress and Its Impact on Overall Health and Longevity. Annals of the New York Academy of Sciences, 2005, 1057, 492-505.	1.8	86
157	Soluble Human Interleukin-6 Receptor. Expression in Insect Cells, Purification and Characterization. FEBS Journal, 1995, 234, 661-669.	0.2	85
158	Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clinical and Experimental Immunology, 1997, 107, 555-561.	1.1	85
159	Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130-Mediated Embryonic Stem Cell Self-Renewal Responses to LIF and HIL-6. Stem Cells, 2002, 20, 119-138.	1.4	85
160	ADAM17, shedding, TACE as therapeutic targets. Pharmacological Research, 2013, 71, 19-22.	3.1	83
161	IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8+ T Cell Function. Cell Reports, 2014, 8, 1318-1327.	2.9	81
162	Distinct Effects of IL-6 Classic and Trans -Signaling in Bone Fracture Healing. American Journal of Pathology, 2018, 188, 474-490.	1.9	81

#	Article	IF	Citations
163	Structure-function analysis of human interleukin-6. FEBS Letters, 1990, 262, 323-326.	1.3	79
164	Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. Journal of Clinical Investigation, 2011, 121, 1692-1708.	3.9	79
165	TLR ligandâ€“induced podosome disassembly in dendritic cells is ADAM17 dependent. Journal of Cell Biology, 2008, 182, 993-1005.	2.3	78
166	IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSFâ€“ and GM-CSFâ€“deficient mice. Blood, 2008, 111, 3978-3985.	0.6	78
167	Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opinion on Therapeutic Targets, 2012, 16, 225-236.	1.5	78
168	Impaired hippocampus-dependent and -independent learning in IL-6 deficient mice. Behavioural Brain Research, 2009, 200, 192-196.	1.2	77
169	Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Letters, 1992, 314, 280-284.	1.3	76
170	Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters, 1997, 239, 29-32.	1.0	76
171	Interleukin-6 in Sepsis and Capillary Leakage Syndrome. Journal of Interferon and Cytokine Research, 2012, 32, 60-65.	0.5	76
172	Enhancing influence of intranasal interleukinâ€6 on slowwave activity and memory consolidation during sleep. FASEB Journal, 2009, 23, 3629-3636.	0.2	75
173	TIMP expression in toxic and cholestatic liver injury in rat. Journal of Hepatology, 1997, 27, 535-544.	1.8	73
174	Hyper-IL-6 Gene Therapy Reverses Fulminant Hepatic Failure. Molecular Therapy, 2001, 3, 683-687.	3.7	73
175	The Stress-Induced Cytokine Interleukin-6 Decreases the Inhibition/Excitation Ratio in the Rat Temporal Cortex via Trans-Signaling. Biological Psychiatry, 2012, 71, 574-582.	0.7	73
176	Allergen-induced IL-6 trans-signaling activates Î³Î´ T cells to promote type 2 and type 17 airway inflammation. Journal of Allergy and Clinical Immunology, 2015, 136, 1065-1073.	1.5	73
177	Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane. Protein Science, 2005, 14, 783-790.	3.1	72
178	Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease. Current Pharmaceutical Design, 2009, 15, 2095-2103.	0.9	72
179	An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood, 2013, 121, 3768-3777.	0.6	72
180	Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17. Scientific Reports, 2016, 6, 25550.	1.6	72

#	Article	IF	Citations
181	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes ofÂPatients. Gastroenterology, 2017, 153, 178-190.e10.	0.6	72
182	Forced Dimerization of gp130 Leads to Constitutive STAT3 Activation, Cytokine-independent Growth, and Blockade of Differentiation of Embryonic Stem Cells. Molecular Biology of the Cell, 2006, 17, 2986-2995.	0.9	71
183	A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor Î² Subunit, Glycoprotein 130. Journal of Immunology, 2015, 195, 237-245.	0.4	71
184	Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling. Journal of Biological Chemistry, 2016, 291, 16186-16196.	1.6	70
185	The three carboxy-terminal amino acids of human interleukin-6 are essential for its biological activity. FEBS Letters, 1990, 273, 95-98.	1.3	69
186	Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. Journal of Autoimmunity, 2010, 34, 29-37.	3.0	69
187	Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. FEBS Journal, 1993, 216, 239-245.	0.2	68
188	Cytokines and Neurotrophins Interact in Normal and Diseased States. Annals of the New York Academy of Sciences, 2000, 917, 322-330.	1.8	68
189	Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. Journal of Cellular and Molecular Medicine, 2011, 15, 994-1004.	1.6	68
190	Semisynthesis of Biologically Active Glycoforms of the Human Cytokine Interleukinâ€…6. Angewandte Chemie - International Edition, 2014, 53, 12125-12131.	7.2	68
191	Cell-typeâ€“restricted anti-cytokine therapy: TNF inhibition from one pathogenic source. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3006-3011.	3.3	68
192	New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 787-803.	8.2	67
193	Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Letters, 1992, 297, 263-265.	1.3	66
194	Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 1597-1607.	3.0	66
195	Natural Soluble Interleukin-15RÎ± Is Generated by Cleavage That Involves the Tumor Necrosis Factor-Î±-converting Enzyme (TACE/ADAM17). Journal of Biological Chemistry, 2004, 279, 40368-40375.	1.6	65
196	ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer. Cancers, 2019, 11, 1736.	1.7	65
197	<scp>ADAM</scp> 17 selectively activates the <scp>IL</scp> â€6 transâ€signaling/ <scp>ERK MAPK</scp> axis in <scp>KRAS</scp> â€addicted lung cancer. EMBO Molecular Medicine, 2019, 11, .	3.3	65
198	Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis, 1988, 9, 555-562.	1.3	64

#	Article	IF	Citations
199	The membraneâ€proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukinâ€6 receptor and interleukinâ€1 receptor II. FEBS Letters, 2012, 586, 1093-1100.	1.3	63
200	ADAM17 is required for EGF-Râ€“induced intestinal tumors via IL-6 trans-signaling. Journal of Experimental Medicine, 2018, 215, 1205-1225.	4.2	63
201	Interleukin-6 signalling in health and disease. F1000Research, 2020, 9, 1013.	0.8	63
202	ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy In vitro. Cancer Research, 2007, 67, 332-338.	0.4	62
203	ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by Î³-secretase. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 234-245.	1.9	62
204	Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochemical Journal, 2001, 353, 663-672.	1.7	60
205	IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. Journal of Neuroimmunology, 2008, 205, 64-72.	1.1	60
206	Structure-guided Optimization of the Interleukin-6 Trans-signaling Antagonist sgp130. Journal of Biological Chemistry, 2008, 283, 27200-27207.	1.6	60
207	A Disintegrin and Metalloprotease 17 Dynamic Interaction Sequence, the Sweet Tooth for the Human Interleukin 6 Receptor. Journal of Biological Chemistry, 2014, 289, 16336-16348.	1.6	60
208	Interleukin-6 biology is coordinated by membrane bound and soluble receptors.. Acta Biochimica Polonica, 2003, 50, 603-611.	0.3	60
209	Rapid Differentiation of a Rare Subset of Adult Human Linâ^'CD34â^'CD38â^' Cells Stimulated by Multiple Growth Factors In Vitro. Blood, 1999, 94, 1926-1932.	0.6	59
210	Novel Regulatory Mechanisms for Generation of the Soluble Leptin Receptor: Implications for Leptin Action. PLoS ONE, 2012, 7, e34787.	1.1	59
211	Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M. Glia, 2015, 63, 132-141.	2.5	59
212	Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer. Gut, 2016, 65, 1139-1150.	6.1	59
213	Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 247-257.	1.1	59
214	Ataxin-10, the Spinocerebellar Ataxia Type 10 Neurodegenerative Disorder Protein, Is Essential for Survival of Cerebellar Neurons. Journal of Biological Chemistry, 2004, 279, 35542-35550.	1.6	58
215	No inhibition of IL-27 signaling by soluble gp130. Biochemical and Biophysical Research Communications, 2005, 326, 724-728.	1.0	58
216	Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biology, 2012, 9, 67-80.	1.5	58

#	Article	IF	Citations
217	Soluble Interleukin 6 Receptor is Biologically Active In Vivo. Cytokine, 1995, 7, 142-149.	1.4	57
218	The IL-6/sIL-6R Fusion Protein Hyper-IL-6 Promotes Neurite Outgrowth and Neuron Survival in Cultured Enteric Neurons. Journal of Interferon and Cytokine Research, 1999, 19, 527-532.	0.5	57
219	The Designer Cytokine Hyper-Interleukin-6 Is a Potent Activator of STAT3-dependent Gene Transcription in Vivoand in Vitro. Journal of Biological Chemistry, 1999, 274, 1257-1266.	1.6	57
220	Astrocytic Alterations in Interleukin-6/Soluble Interleukin-6 Receptor Î± Double-Transgenic Mice. American Journal of Pathology, 2000, 157, 1485-1493.	1.9	57
221	ADAM17: An Emerging Therapeutic Target for Lung Cancer. Cancers, 2019, 11, 1218.	1.7	57
222	Transcription Factor NFATc2 Controls the Emergence of Colon Cancer Associated with IL-6â€“Dependent Colitis. Cancer Research, 2012, 72, 4340-4350.	0.4	56
223	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood, 2020, 136, 2051-2064.	0.6	56
224	Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2) Up-regulation by interleukin-6 and transforming growth factor Î²1. FEBS Letters, 1992, 313, 143-147.	1.3	55
225	Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle, 2013, 12, 3421-3432.	1.3	55
226	Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature, 2019, 574, 63-68.	13.7	55
227	Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics. ELife, 2016, 5, .	2.8	55
228	Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.. Journal of Experimental Medicine, 1994, 180, 2395-2400.	4.2	54
229	Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. International Immunology, 2007, 19, 685-693.	1.8	54
230	gp130 dimerization in the absence of ligand: Preformed cytokine receptor complexes. Biochemical and Biophysical Research Communications, 2006, 346, 649-657.	1.0	53
231	The interleukin 6 pathway and atherosclerosis. Lancet, The, 2012, 380, 338.	6.3	53
232	An Evaluation of 2,5-Norbornadiene as a Reversible Inhibitor of Ethylene Action in Deepwater Rice. Plant Physiology, 1987, 84, 395-398.	2.3	52
233	Evidence for the importance of a positive charge and an Î±-helical structure of the C-terminus for biological activity of human IL-6. FEBS Letters, 1991, 282, 265-267.	1.3	52
234	Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. FEBS Journal, 1994, 223, 265-274.	0.2	52

#	Article	IF	Citations
235	Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology, 2012, 217, 996-1004.	0.8	52
236	Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells. Stem Cells, 2017, 35, 898-908.	1.4	52
237	N-Linked Glycosylation Is Essential for the Stability but Not the Signaling Function of the Interleukin-6 Signal Transducer Glycoprotein 130. Journal of Biological Chemistry, 2010, 285, 1781-1789.	1.6	51
238	The Role of IL-6Trans-Signaling in Vascular Leakage: Implications for Ovarian Hyperstimulation Syndrome in a Murine Model. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E472-E484.	1.8	51
239	Identification of Canonical Tyrosine-dependent and Non-canonical Tyrosine-independent STAT3 Activation Sites in the Intracellular Domain of the Interleukin 23 Receptor. Journal of Biological Chemistry, 2013, 288, 19386-19400.	1.6	51
240	Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor. Journal of Virology, 2009, 83, 5117-5126.	1.5	50
241	Senescenceâ€associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB Journal, 2014, 28, 4847-4856.	0.2	50
242	GP130 stimulation and the maintenance of stem cells. Trends in Biotechnology, 2002, 20, 417-419.	4.9	49
243	Progressive and Controlled Development of Mouse Dendritic Cells from Flt3+CD11b+ Progenitors In Vitro. Journal of Immunology, 2005, 174, 2552-2562.	0.4	49
244	Is Interleukin-6 Receptor Blockade the Holy Grail for Inflammatory Diseases?. Clinical Pharmacology and Therapeutics, 2010, 87, 396-398.	2.3	49
245	ADAM17 controls IL-6 signaling by cleavage of the murine IL-6RÎ± from the cell surface of leukocytes during inflammatory responses. Journal of Leukocyte Biology, 2016, 99, 749-760.	1.5	49
246	Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling. Scientific Reports, 2017, 7, 44053.	1.6	49
247	TIMP-1 protein expression is stimulated by IL-1Î² and IL-6 in primary rat hepatocytes. FEBS Letters, 1994, 349, 45-49.	1.3	48
248	Combining Two Mutations of Human Interleukin-6 That Affect gp130 Activation Results in a Potent Interleukin-6 Receptor Antagonist on Human Myeloma Cells. Journal of Biological Chemistry, 1995, 270, 8158-8163.	1.6	48
249	Cytokines as Therapeutic Drugs. Journal of Interferon and Cytokine Research, 2002, 22, 505-516.	0.5	48
250	Increased inflammation and lethality of Dusp1^{â^'/â^'} mice in polymicrobial peritonitis models. Immunology, 2010, 131, 395-404.	2.0	48
251	Forced Homo- and Heterodimerization of All gp130-Type Receptor Complexes Leads to Constitutive Ligand-independent Signaling and Cytokine-independent Growth. Molecular Biology of the Cell, 2010, 21, 2797-2807.	0.9	48
252	Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. Journal of Autoimmunity, 2013, 40, 74-85.	3.0	48

#	Article	IF	Citations
253	Hepatocytes Contribute to Immune Regulation in the Liver by Activation of the Notch Signaling Pathway in T Cells. Journal of Immunology, 2013, 191, 5574-5582.	0.4	48
254	A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding. FEBS Journal, 1999, 263, 438-446.	0.2	47
255	Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clinical and Experimental Immunology, 2002, 130, 107-114.	1.1	47
256	Short-term TNFÎ± shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 3355-3367.	1.9	47
257	Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. Journal of Leukocyte Biology, 2013, 94, 791-802.	1.5	47
258	The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Letters, 1995, 360, 43-46.	1.3	46
259	Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochemical Journal, 2001, 353, 663.	1.7	46
260	Updating interleukin-6 classic- and trans-signaling. Signal Transduction, 2006, 6, 240-259.	0.7	46
261	Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H987-H996.	1.5	46
262	Myeloid A Disintegrin and Metalloproteinase Domain 10 Deficiency Modulates Atherosclerotic Plaque Composition by Shifting the Balance from Inflammation toward Fibrosis. American Journal of Pathology, 2015, 185, 1145-1155.	1.9	46
263	Interleukin 6/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. Croatian Medical Journal, 2016, 57, 89-98.	0.2	46
264	Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates. Circulation Genomic and Precision Medicine, 2019, 12, e002413.	1.6	46
265	Degradome of soluble ADAM10 and ADAM17 metalloproteases. Cellular and Molecular Life Sciences, 2020, 77, 331-350.	2.4	46
266	Cytokines Are a Therapeutic Target for the Prevention of Inflammation-Induced Cancers. , 2007, 174, 57-66.		46
267	Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. European Journal of Immunology, 2001, 31, 2071-2079.	1.6	45
268	Peripheral Nerve Regeneration and NGF-Dependent Neurite Outgrowth of Adult Sensory Neurons Converge on STAT3 Phosphorylation Downstream of Neuropoietic Cytokine Receptor gp130. Journal of Neuroscience, 2014, 34, 13222-13233.	1.7	45
269	Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor Î± Ectodomain Shedding. Journal of Biological Chemistry, 2014, 289, 3080-3093.	1.6	45
270	IL-6 Trans-Signaling Drives Murine Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 132-142.	3.0	45

#	Article	IF	Citations
271	IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants. Journal of Allergy and Clinical Immunology, 2020, 146, 652-666.e11.	1.5	45
272	Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. FEBS Journal, 2000, 267, 3604-3612.	0.2	44
273	Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transplantation, 2010, 16, 1195-1206.	1.3	44
274	A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochemical Journal, 2012, 445, 135-144.	1.7	44
275	Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1494-1505.	2.5	44
276	Coordination of interleukin-6 biology by membrane bound and soluble receptors. Advances in Experimental Medicine and Biology, 2001, 495, 145-151.	0.8	44
277	Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling. Biochemical Journal, 2006, 398, 577-583.	1.7	43
278	ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis, 2015, 18, 13-22.	3.7	43
279	Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer. Methods in Molecular Biology, 2018, 1725, 127-140.	0.4	43
280	Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget, 2014, 5, 2131-2148.	0.8	43
281	Differential effects of phorbol esters on c-fos and c-myc and ornithine decarboxylase gene expression in mouse skin in vivo. Carcinogenesis, 1988, 9, 831-835.	1.3	41
282	Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 523-536.	1.4	41
283	Interleukin 6 trans-signalling and risk of future cardiovascular events. Cardiovascular Research, 2019, 115, 213-221.	1.8	41
284	Role of IL-6 trans-signaling in CCl4 induced liver damage. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 1054-1061.	1.8	40
285	Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis. Frontiers in Immunology, 2017, 8, 1115.	2.2	40
286	The function of the soluble IL-6 receptor in vivo. Immunology Letters, 1996, 54, 177-184.	1.1	39
287	d(GGGT)₄and r(GGGU)₄are both HIV-1 inhibitors and interleukin-6 receptor aptamers. RNA Biology, 2013, 10, 216-227.	1.5	39
288	Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display. Journal of Virology, 2006, 80, 8510-8520.	1.5	38

#	Article	IF	Citations
289	Interleukinâ€6 Transâ€Signaling Exacerbates Inflammation and Renal Pathology in Lupusâ€Prone Mice. Arthritis and Rheumatism, 2013, 65, 2691-2702.	6.7	38
290	The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane. FEBS Letters, 2003, 538, 113-116.	1.3	36
291	Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease. Digestive Diseases, 2012, 30, 492-499.	0.8	36
292	Dendritic cell development requires histone deacetylase activity. European Journal of Immunology, 2014, 44, 2478-2488.	1.6	36
293	â€œActivatedâ€•STAT Proteins: A Paradoxical Consequence of Inhibited JAK-STAT Signaling in Cytomegalovirus-Infected Cells. Journal of Immunology, 2014, 192, 447-458.	0.4	36
294	Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure. Journal of Clinical Investigation, 2018, 128, 5056-5072.	3.9	36
295	A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1). FEBS Letters, 1995, 372, 177-180.	1.3	35
296	The Membrane Proximal Cytokine Receptor Domain of the Human Interleukin-6 Receptor Is Sufficient for Ligand Binding but Not for gp130 Association. Journal of Biological Chemistry, 1998, 273, 21374-21379.	1.6	35
297	Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. European Respiratory Journal, 2022, 59, 2002248.	3.1	35
298	Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Journal of Experimental Medicine, 2022, 219, .	4.2	35
299	Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, PoznaÅ„, Poland. Human Gene Therapy, 1995, 6, 805-811.	1.4	34
300	Introduction to Stem Cell Biology in Vitro: Threshold to the Future. Annals of the New York Academy of Sciences, 1999, 872, 1-8.	1.8	34
301	Trp53 Deficiency Protects against Acute Intestinal Inflammation. Journal of Immunology, 2013, 191, 837-847.	0.4	34
302	Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. BMC Cancer, 2015, 15, 975.	1.1	34
303	The soluble interleukin-6 receptor and related proteins. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 787-797.	2.2	34
304	Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain, Behavior, and Immunity, 2015, 43, 149-158.	2.0	34
305	GP130 activation induces myeloma and collaborates with MYC. Journal of Clinical Investigation, 2014, 124, 5263-5274.	3.9	34
306	BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 916-930.	3.9	34

#	Article	IF	Citations
307	The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget, 2016, 7, 51096-51106.	0.8	34
308	The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Experimental Hematology, 2000, 28, 365-372.	0.2	33
309	Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo. Virology, 2000, 270, 299-309.	1.1	33
310	Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. Aids, 2002, 16, F9-F18.	1.0	33
311	Increased inflammation and impaired resistance to Chlamydophila pneumoniae infection in Dusp1-/- mice: critical role of IL-6. Journal of Leukocyte Biology, 2010, 88, 579-587.	1.5	33
312	The induction of ornithine decarboxylase by the tumor promoter TPA is controlled at the post-transcriptional level in murine Swiss 3T3 fibroblasts. Biochemical and Biophysical Research Communications, 1987, 147, 219-225.	1.0	32
313	Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. Journal of Cellular and Molecular Medicine, 2011, 15, 484-500.	1.6	32
314	Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. European Journal of Cell Biology, 2011, 90, 495-504.	1.6	32
315	The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E411-E420.	1.8	32
316	Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency. Nature Communications, 2020, 11, 4977.	5.8	32
317	Short-term growth response of deep-water rice to submergence and ethylene. Plant Science, 1985, 38, 129-134.	1.7	31
318	Soluble human interleukin-6-receptor modulates interleukin-6-dependentN-glycosylation of Î±1-protease inhibitor secreted by HepG2 cells. FEBS Letters, 1992, 306, 257-261.	1.3	31
319	Yeast expression of the cytokine receptor domain of the soluble interleukin-6 receptor. Journal of Immunological Methods, 1996, 199, 47-54.	0.6	31
320	A New Type of Cytokine Receptor Antagonist Directly Targeting gp130. Journal of Biological Chemistry, 1998, 273, 27213-27219.	1.6	31
321	Gp130-Signaling synergizes with FL and TPO for the long-term expansion of cord blood progenitors. Leukemia, 1999, 13, 2036-2048.	3.3	31
322	Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectin. Blood, 2000, 96, 2432-2439.	0.6	31
323	Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation. Journal of Immunology, 2005, 175, 4024-4029.	0.4	31
324	A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotechnology, 2012, 12, 8.	1.7	31

#	Article	IF	Citations
325	Stabilized Interleukin-6 receptor binding RNA aptamers. RNA Biology, 2014, 11, 57-65.	1.5	31
326	Mucus Detachment by Host Metalloprotease Meprin Î² Requires Shedding of Its Inactive Pro-form, which Is Abrogated by the Pathogenic Protease RgpB. Cell Reports, 2017, 21, 2090-2103.	2.9	31
327	Mutations in Craniosynostosis Patients Cause Defective Interleukin-11 Receptor Maturation and Drive Craniosynostosis-like Disease in Mice. Cell Reports, 2018, 25, 10-18.e5.	2.9	31
328	Conservation of ILâ€6 transâ€signaling mechanisms controlling Lâ€selectin adhesion by feverâ€range thermal stress. European Journal of Immunology, 2007, 37, 2856-2867.	1.6	30
329	Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. Journal of Hepatology, 2011, 54, 922-929.	1.8	30
330	Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 275-287.	1.9	30
331	In VitroReconstitution of Recognition and Activation Complexes between Interleukin-6 and gp130â€. Biochemistry, 2001, 40, 7593-7603.	1.2	29
332	Transglutaminase-catalyzed covalent multimerization of camelidae anti-human TNF single domain antibodies improves neutralizing activity. Journal of Biotechnology, 2009, 142, 170-178.	1.9	29
333	Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 290-301.	1.8	29
334	Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling. Journal of Biological Chemistry, 2012, 287, 13743-13751.	1.6	29
335	Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling. Journal of Biological Chemistry, 2012, 287, 13743-13751.	1.6	29
336	Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease. Clinical Pharmacology and Therapeutics, 2012, 91, 574-576.	2.3	29
337	IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood, 2019, 134, 2092-2106.	0.6	29
338	Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on Î±1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochemical Journal, 1998, 329, 335-339.	1.7	28
339	Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. European Journal of Cell Biology, 2003, 82, 75-86.	1.6	28
340	The Soluble Interleukinâ€6 Receptora. Annals of the New York Academy of Sciences, 1995, 762, 207-221.	1.8	28
341	TNF-Î±-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia, 2010, 24, 51-57.	3.3	28
342	Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 649-658.	1.8	28

#	Article	IF	Citations
343	The Regenerative Activity of Interleukin-6. Methods in Molecular Biology, 2013, 982, 59-77.	0.4	28
344	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases, 2015, 74, 1317-1324.	0.5	28
345	Interleukin 6â€“dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology, 2017, 65, 1600-1611.	3.6	28
346	Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3. Molecular Therapy - Nucleic Acids, 2019, 16, 419-433.	2.3	28
347	Identification of Single Amino Acid Residues of Human IL-6 Involved in Receptor Binding and Signal Initiation. Journal of Interferon and Cytokine Research, 1996, 16, 569-576.	0.5	27
348	Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunology Letters, 2000, 74, 81-86.	1.1	27
349	The designer cytokine hyper-IL-6 mediates growth inhibition and GMâ€“CSF-dependent rejection of B16 melanoma cells. Oncogene, 2001, 20, 972-979.	2.6	27
350	IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts. Journal of Neuroimmunology, 2008, 196, 41-48.	1.1	27
351	Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair. Oncogenesis, 2016, 5, e270-e270.	2.1	27
352	Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified Î±-Synuclein Degradation Properties. Frontiers in Cell and Developmental Biology, 2021, 9, 581805.	1.8	27
353	Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6. Journal of Biological Chemistry, 1998, 273, 2858-2865.	1.6	26
354	The upper cytokine-binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIF receptor complex 1 1Edited by M. Yaniv. Journal of Molecular Biology, 2002, 315, 637-646.	2.0	26
355	Multilevel Regulation of IL-6R by IL-6-sIL-6R Fusion Protein According to the Primitiveness of Peripheral Blood-Derived CD133+Cells. Stem Cells, 2006, 24, 1302-1314.	1.4	26
356	Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling. British Journal of Cancer, 2007, 97, 1513-1522.	2.9	26
357	mTNF reverse signalling induced by TNFÎ± antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut, 2013, 62, 376-386.	6.1	26
358	IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2019, 82, 145-159.	2.0	26
359	Blocking only the bad side of IL-6 in inflammation and cancer. Cytokine, 2021, 148, 155690.	1.4	26
360	Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119143.	1.9	26

#	Article	IF	Citations
361	Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Letters, 1995, 357, 33-36.	1.3	25
362	Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells. Journal of Immunology, 2000, 165, 4133-4140.	0.4	25
363	ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. Cell Death and Disease, 2013, 4, e954-e954.	2.7	25
364	Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35. PLoS ONE, 2014, 9, e107990.	1.1	25
365	Peripheral and central blockade of interleukin-6 trans-signaling differentially affects sleep architecture. Brain, Behavior, and Immunity, 2015, 50, 178-185.	2.0	25
366	Participation of Two Ser-Ser-Phe-Tyr Repeats in Interleukin-6 (IL-6)-Binding Sites of the Human IL-6 Receptor. FEBS Journal, 1996, 238, 714-723.	0.2	24
367	Generation and function of the soluble interleukin-6 receptor. Biochemical Society Transactions, 1999, 27, 211-219.	1.6	24
368	The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons. Biochemical and Biophysical Research Communications, 2002, 295, 532-539.	1.0	24
369	Membraneâ€bound and Soluble Interleukinâ€6 Receptor: Studies on Structure, Regulation of Expression, and Signal Transductiona. Annals of the New York Academy of Sciences, 1995, 762, 222-237.	1.8	24
370	Glycoprotein 130 Receptor Signaling Mediates Î±-Cell Dysfunction in a Rodent Model of Type 2 Diabetes. Diabetes, 2014, 63, 2984-2995.	0.3	24
371	Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling. Cytokine, 2017, 92, 118-123.	1.4	24
372	The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. Carcinogenesis, 2020, 41, 527-538.	1.3	24
373	Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. Journal of Immunological Methods, 1999, 223, 171-183.	0.6	23
374	New perspectives on the design of cytokines and growth factors. Trends in Biotechnology, 2000, 18, 455-461.	4.9	23
375	A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regulatory Peptides, 2008, 146, 189-196.	1.9	23
376	Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing. BMC Genomics, 2012, 13, 500.	1.2	23
377	Oncogenic deletion mutants of gp130 signal from intracellular compartments. Journal of Cell Science, 2014, 127, 341-53.	1.2	23
378	The Role of Metalloproteinase ADAM17 in Regulating ICOS Ligandâ€"Mediated Humoral Immune Responses. Journal of Immunology, 2014, 193, 2753-2763.	0.4	23

#	Article	IF	Citations
379	RAID3 - An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity. RNA Biology, 2015, 12, 1043-1053.	1.5	23
380	â€œFamily reunionâ€•â€“ A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines. Cytokine and Growth Factor Reviews, 2015, 26, 471-474.	3.2	23
381	Frontline Science: Proliferation of Ly6C+ monocytes during urinary tract infections is regulated by IL-6 trans-signaling. Journal of Leukocyte Biology, 2018, 103, 13-22.	1.5	23
382	Therapeutic targeting of IL-6 trans-signaling. Cytokine, 2021, 144, 155577.	1.4	23
383	Identification of the factor XII contact activation site enables sensitive coagulation diagnostics. Nature Communications, 2021, 12, 5596.	5.8	23
384	The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opinion on Investigational Drugs, 1997, 6, 237-266.	1.9	22
385	Interleukinâ€6â€Type Cytokines and Their Receptors for Gene Therapy of Melanomaa. Annals of the New York Academy of Sciences, 1995, 762, 361-374.	1.8	22
386	Polycomb Group Protein Bmi1 Promotes Hematopoietic Cell Development from Embryonic Stem Cells. Stem Cells and Development, 2012, 21, 121-132.	1.1	22
387	Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opinion on Investigational Drugs, 2012, 21, 773-783.	1.9	22
388	Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin Î±, Meprin Î² and MT1-MMP. International Journal of Molecular Sciences, 2019, 20, 3677.	1.8	22
389	Microheterogeneity of human interleukin 6 synthesized by transfected NIH/3T3 cells: Comparison with human monocytes, fibroblasts and endothelial cells. European Journal of Immunology, 1990, 20, 883-887.	1.6	21
390	ALTERED PULMONARY INTERLEUKIN-6 SIGNALING IN PRETERM INFANTS DEVELOPING BRONCHOPULMONARY DYSPLASIA. Experimental Lung Research, 2008, 34, 694-706.	0.5	21
391	The Amino Acid Exchange R28E in Ciliary Neurotrophic Factor (CNTF) Abrogates Interleukin-6 Receptor-dependent but Retains CNTF Receptor-dependent Signaling via Glycoprotein 130 (gp130)/Leukemia Inhibitory Factor Receptor (LIFR). Journal of Biological Chemistry, 2014, 289, 18442-18450.	1.6	21
392	Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica, 2017, 102, 381-390.	1.7	21
393	A variant in IL6ST with a selective IL-11 signaling defect in human and mouse. Bone Research, 2020, 8, 24.	5.4	21
394	Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate. Blood, 2021, 137, 1392-1405.	0.6	21
395	Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro. Experimental Hematology, 2001, 29, 146-155.	0.2	20
396	gp130 activation is regulated by D2â€“D3 interdomain connectivity. Biochemical Journal, 2013, 450, 487-496.	1.7	20

#	Article	IF	Citations
397	Mycobacterium simiae Infection in Two Unrelated Patients with Different Forms of Inherited IFN-Î³R2 Deficiency. Journal of Clinical Immunology, 2014, 34, 904-909.	2.0	20
398	cDNA-cloning, sequencing and expression in glucocorticoid-stimulated quiescent Swiss 3T3 fibroblasts of mouse lipocortin I. Biochemical and Biophysical Research Communications, 1989, 159, 155-162.	1.0	19
399	Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production. Immunology Letters, 2000, 71, 143-148.	1.1	19
400	IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling. Journal of Leukocyte Biology, 2011, 91, 427-435.	1.5	19
401	The SLAM family member CD84 is regulated by ADAM10 and calpain in platelets. Journal of Thrombosis and Haemostasis, 2012, 10, 2581-2592.	1.9	19
402	In vivo evidence suggesting reciprocal renal hypoxiaâ€inducible factorâ€1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and nonâ€hypoxic stimuli. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 262-272.	0.9	19
403	Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine, 2017, 96, 8-15.	1.4	19
404	Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib. Frontiers in Physiology, 2017, 8, 775.	1.3	19
405	Differing Outcome of Experimental Autoimmune Encephalitis in Macrophage/Neutrophil- and T Cell-Specific gp130-Deficient Mice. Frontiers in Immunology, 2018, 9, 836.	2.2	19
406	Human CNTF and related cytokines: effects on DRG neurone survival. NeuroReport, 1995, 7, 153-157.	0.6	18
407	Possible role of human interleukin-6 and soluble interleukin-6 receptor in hepatitis B virus infection. Journal of Viral Hepatitis, 2001, 8, 186-193.	1.0	18
408	Dendritic cell lineage commitment is instructed by distinct cytokine signals. European Journal of Cell Biology, 2012, 91, 515-523.	1.6	18
409	<scp>TNF</scp>Î± cleavage beyond <scp>TACE</scp>/<scp>ADAM</scp>17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis. EMBO Molecular Medicine, 2013, 5, 970-972.	3.3	18
410	Instructive Role of the Microenvironment in Preventing Renal Fibrosis. Stem Cells Translational Medicine, 2017, 6, 992-1005.	1.6	18
411	Meprin Î² induces activities of A disintegrin and metalloproteinases 9, 10, and 17 by specific prodomain cleavage. FASEB Journal, 2019, 33, 11925-11940.	0.2	18
412	The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients. Frontiers in Aging Neuroscience, 2019, 11, 182.	1.7	18
413	Interleukin-6 plays a critical role in aldosterone-induced macrophage recruitment and infiltration in the myocardium. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165627.	1.8	18
414	Natural Glycoforms of Human Interleukin 6 Show Atypical Plasma Clearance. Angewandte Chemie - International Edition, 2021, 60, 13380-13387.	7.2	18

#	Article	IF	Citations
415	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. Circulation Research, 2021, 129, 804-820.	2.0	18
416	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight, 2019, 4, .	2.3	18
417	Effect of Soluble Interleukin-6 Receptor on Interleukin-6 Synthesis in Human Skin Fibroblasts. Biochemical and Biophysical Research Communications, 1996, 227, 318-321.	1.0	17
418	Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation. Journal of Immunology, 2016, 197, 3705-3715.	0.4	17
419	Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells. PLoS ONE, 2020, 15, e0232612.	1.1	17
420	ADAM17 Deficiency Protects against Pulmonary Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 183-195.	1.4	17
421	A disintegrin and metalloprotease 10 (ADAM10) is a central regulator of murine liver tissue homeostasis. Oncotarget, 2016, 7, 17431-17441.	0.8	17
422	Phagosomal signalling of the C-type lectin receptor Dectin-1 is terminated by intramembrane proteolysis. Nature Communications, 2022, 13, 1880.	5.8	17
423	Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130. Cytokine, 1995, 7, 398-407.	1.4	16
424	gp130-Stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. Experimental Hematology, 2001, 29, 822-832.	0.2	16
425	Interleukinâ€6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Experimental Dermatology, 2016, 25, 305-310.	1.4	16
426	Laboratory diagnostics of murine blood for detection of mouse cytomegalovirus (MCMV)-induced hepatitis. Scientific Reports, 2018, 8, 14823.	1.6	16
427	Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells. PLoS ONE, 2018, 13, e0203395.	1.1	16
428	Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles. Cells, 2020, 9, 1307.	1.8	16
429	Local and systemic effects of interleukinâ€6 (ILâ€6) in inflammation and cancer. FEBS Letters, 2022, 596, 557-566.	1.3	16
430	Direct Determination of the Interleukin-6 Binding Epitope of the Interleukin-6 Receptor by NMR Spectroscopy. Journal of Biological Chemistry, 2004, 279, 571-576.	1.6	15
431	Strawberry notch homolog 2 is a novel inflammatory response factor predominantly but not exclusively expressed by astrocytes in the central nervous system. Glia, 2015, 63, 1738-1752.	2.5	15
432	KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. Blood Cancer Journal, 2016, 6, e398-e398.	2.8	15

#	Article	IF	Citations
433	Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells. Journal of Immunology, 2018, 201, 3106-3118.	0.4	15
434	ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury. Brain, Behavior, and Immunity, 2019, 80, 129-145.	2.0	15
435	Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. Journal of Hepatology, 2021, 74, 407-418.	1.8	15
436	Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. American Journal of Physiology - Cell Physiology, 2021, 320, C554-C565.	2.1	15
437	New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?. Expert Opinion on Investigational Drugs, 1999, 8, 1327-1349.	1.9	14
438	Analysis of the Leukemia Inhibitory Factor Receptor Functional Domains by Chimeric Receptors and Cytokinesâ€. Biochemistry, 2003, 42, 5244-5252.	1.2	14
439	ADAM17-overexpressing breast cancer cells selectively targeted by antibodyâ€“toxin conjugates. Cancer Immunology, Immunotherapy, 2013, 62, 411-421.	2.0	14
440	Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. Medicine (United States), 2015, 94, e853.	0.4	14
441	Parathyroid hormone induces expression and proteolytic processing of Rankl in primary murine osteoblasts. Bone, 2016, 92, 85-93.	1.4	14
442	Regulation of Fibrotic Processes in the Liver by ADAM Proteases. Cells, 2019, 8, 1226.	1.8	14
443	Impaired mechanical, heat, and cold nociception in a murine model of genetic TACE/ADAM17 knockdown. FASEB Journal, 2019, 33, 4418-4431.	0.2	14
444	Alternative assay procedures for cytokines and soluble receptors of the IL-6 family. Journal of Immunological Methods, 1996, 195, 153-159.	0.6	13
445	SOLUBLE INTERLEUKIN 6 (IL-6) RECEPTOR INFLUENCES THE EXPRESSION OF THE PROTOONCOGENE junB AND THE PRODUCTION OF FIBRINOGEN IN THE HepG2 HUMAN HEPATOMA CELL LINE AND PRIMARY RAT HEPATOCYTES. Cytokine, 1998, 10, 620-626.	1.4	13
446	Novel Potent Proline-Based Metalloproteinase Inhibitors: Design, (Radio)Synthesis, and First in Vivo Evaluation as Radiotracers for Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 9541-9559.	2.9	13
447	A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing. Biochemical and Biophysical Research Communications, 2016, 470, 870-876.	1.0	13
448	Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro. Scientific Reports, 2020, 10, 21612.	1.6	13
449	Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors. Frontiers in Cell and Developmental Biology, 2021, 9, 688314.	1.8	13
450	The role of ADAM17 in the T-cell response against bacterial pathogens. PLoS ONE, 2017, 12, e0184320.	1.1	13

#	Article	IF	Citations
451	Cancer-associated mutations in the canonical cleavage site do not influence CD99 shedding by the metalloprotease meprin Î² but alter cell migration in vitro. Oncotarget, 2017, 8, 54873-54888.	0.8	13
452	ADAM17 orchestrates Interleukin-6, TNFÎ± and EGF-R signaling in inflammation and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119141.	1.9	13
453	Effect of Submergence on the Cell Wall Composition of Deep-Water Rice Internodes. Plant Physiology, 1984, 76, 106-111.	2.3	12
454	Site-directed mutagenesis of human CNTF: Functional analysis of recombinant variants. Journal of Neuroscience Research, 1995, 40, 826-835.	1.3	12
455	Differential response of neuronal cells to a fusion protein of ciliary neurotrophic factor/soluble CNTF-receptor and leukemia inhibitory factor. FEBS Journal, 2002, 269, 3023-3031.	0.2	12
456	Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors. Leukemia, 2002, 16, 2122-2128.	3.3	12
457	Interleukin 27 induces differentiation of neural C6-precursor cells into astrocytes. Biochemical and Biophysical Research Communications, 2007, 364, 483-487.	1.0	12
458	Interleukin-6 Trans-Signaling Regulates Glycogen Consumption After<scp>d</scp>-Galactosamine-Induced Liver Damage. Journal of Interferon and Cytokine Research, 2009, 29, 711-718.	0.5	12
459	Suppressor of Cytokine Signaling 3 in Macrophages Prevents Exacerbated Interleukin-6-Dependent Arginase-1 Activity and Early Permissiveness to Experimental Tuberculosis. Frontiers in Immunology, 2017, 8, 1537.	2.2	12
460	A new multiple trauma model of the mouse. BMC Musculoskeletal Disorders, 2017, 18, 468.	0.8	12
461	Oncostatin M induces hyperalgesic priming and amplifies signaling of cAMP to ERK by RapGEF2 and PKA. Journal of Neurochemistry, 2021, 157, 1821-1837.	2.1	12
462	Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19. Lancet Rheumatology, The, 2021, 3, e96-e97.	2.2	12
463	Multiple Roles of IL6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis. Cancer Research, 2021, 81, 4766-4777.	0.4	12
464	Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. PLoS ONE, 2017, 12, e0179099.	1.1	12
465	Expression of a Biologically Active Murine Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) in Baculovirus-Infected Insect Cells. Purification and Tissue Distribution in the Rat. FEBS Journal, 1995, 234, 485-491.	0.2	11
466	Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130. FEBS Letters, 1995, 369, 187-191.	1.3	11
467	Synthetic Mimetics of the gp130 Binding Site for Viral Interleukinâ€6 as Inhibitors of the vILâ€6â€“gp130 Interaction. Chemical Biology and Drug Design, 2008, 71, 494-500.	1.5	11
468	IL-6-trans-signalling increases rapid-eye-movement sleep in rats. European Journal of Pharmacology, 2009, 613, 141-145.	1.7	11

#	Article	IF	Citations
469	The biology of interleukin-6 in the 21st century. Seminars in Immunology, 2014, 26, 1.	2.7	11
470	Activation of the antiâ€inflammatory reflex blocks lipopolysaccharideâ€induced decrease in synaptic inhibition in the temporal cortex of the rat. Journal of Neuroscience Research, 2015, 93, 859-865.	1.3	11
471	Pharmacologic IL-6RÎ± inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 308-321.	1.8	11
472	ADAM-Mediated Signalling Pathways in Gastrointestinal Cancer Formation. International Journal of Molecular Sciences, 2020, 21, 5133.	1.8	11
473	IL-6 Trans-Signaling in the Brain Influences the Metabolic Phenotype of the 3xTg-AD Mouse Model of Alzheimerâ€™s Disease. Cells, 2020, 9, 1605.	1.8	11
474	Interleukin-6 controls recycling and degradation, but not internalization of its receptors. Journal of Biological Chemistry, 2021, 296, 100434.	1.6	11
475	Designing Cytokine Variants by Phage-Display. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 173-179.	0.6	11
476	Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation. International Journal of Molecular Sciences, 2019, 20, 2198.	1.8	10
477	IL-6-induced FOXO1 activity determines the dynamics of metabolism in CD8 TÂcells cross-primed by liver sinusoidal endothelial cells. Cell Reports, 2022, 38, 110389.	2.9	10
478	Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19. Frontiers in Immunology, 2022, 13, .	2.2	10
479	Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells. FEBS Letters, 1998, 429, 412-416.	1.3	9
480	Effects of Blockade of Peripheral Interleukin-6 Trans-Signaling on Hippocampus-Dependent and Independent Memory in Mice. Journal of Interferon and Cytokine Research, 2013, 33, 254-260.	0.5	9
481	Interleukin 6 trans-signaling regulates basal synaptic transmission and sensitivity to pentylenetetrazole-induced seizures in mice. Synapse, 2017, 71, e21984.	0.6	9
482	The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology, 2021, 60, 2852-2861.	0.9	9
483	The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis. Oncotarget, 2018, 9, 12941-12958.	0.8	9
484	Specific Targeting of Cytokine-Secreting Cells: A Bispecific Diabody Recognizing Human Interleukin-6 and CD3 Induces T Cell-Mediated Killing. Journal of Interferon and Cytokine Research, 1998, 18, 783-791.	0.5	8
485	Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage. Cytokine, 2019, 114, 1-5.	1.4	8
486	NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy. Cancers, 2021, 13, 455.	1.7	8

#	Article	IF	Citations
487	Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells. International Journal of Molecular Sciences, 2021, 22, 5086.	1.8	8
488	The metalloprotease ADAM10 generates soluble interleukin-2 receptor alpha (sCD25) inÂvivo. Journal of Biological Chemistry, 2022, 298, 101910.	1.6	8
489	Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition. Journal of Immunological Methods, 2004, 291, 93-100.	0.6	7
490	The two facets of gp130 signalling in liver tumorigenesis. Seminars in Immunopathology, 2021, 43, 609-624.	2.8	7
491	Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectin. Blood, 2000, 96, 2432-2439.	0.6	7
492	Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis. Gastroenterology, 2000, 118, A863.	0.6	6
493	CYTOKINES COME OF AGE. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1592, 213-214.	1.9	6
494	Genetic manipulations utilizing albumin and alpha-fetoprotein promoter/enhancers affect both hepatocytes and oval cells. Hepatology, 2004, 40, 759-759.	3.6	6
495	Residues 77-95 of the Human Interleuken-6 Protein are Responsible for Receptor Binding and Residues 41-56 for Signal Transduction. Annals of the New York Academy of Sciences, 2006, 762, 400-402.	1.8	6
496	TIMPâ€1 Protein Expression Is Stimulated by ILâ€1Î² and ILâ€6 in Primary Rat Hepatocytes. Annals of the New York Academy of Sciences, 1995, 762, 462-464.	1.8	6
497	Tâ€cell immunoglobulin and mucin domainÂ2 (<scp>TIM</scp>â€2) is a target of <scp>ADAM</scp>10â€mediated ectodomain shedding. FEBS Journal, 2014, 281, 157-174.	2.2	6
498	CDP-870. Celltech/Pfizer. Current Opinion in Investigational Drugs, 2003, 4, 588-92.	2.3	6
499	Mechanisms of interorgan crosstalk in health and disease. FEBS Letters, 2022, 596, 529-533.	1.3	6
500	Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc). Frontiers in Pharmacology, 0, 13, .	1.6	6
501	Identification of residues in the putative 5th helical region of human interleukin-6, important for activation of the IL-6 signal transducer, gp130. FEBS Letters, 1996, 395, 235-240.	1.3	5
502	The solution structure of the membrane-proximal cytokine receptor domain of the human interleukin-6 receptor. Biological Chemistry, 2006, 387, 1255-1259.	1.2	5
503	Functional Characterization of Colon-Cancer-Associated Variants in ADAM17 Affecting the Catalytic Domain. Biomedicines, 2020, 8, 463.	1.4	5
504	Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Advances in Experimental Medicine and Biology, 2001, 495, 411-418.	0.8	5

#	Article	IF	Citations
505	Necroptosis, ADAM proteases and intestinal (dys)function. International Review of Cell and Molecular Biology, 2020, 353, 83-152.	1.6	5
506	Rapid Differentiation of a Rare Subset of Adult Human Linâ"CD34â"CD38â" Cells Stimulated by Multiple Growth Factors In Vitro. Blood, 1999, 94, 1926-1932.	0.6	5
507	More about genetically modified tumour vaccines. Gene Therapy, 1998, 5, 147-148.	2.3	4
508	AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS. Cytokine, 2000, 12, 1395-1399.	1.4	4
509	The structure of the unliganded extracellular domain of the interleukin-6 signal transducer gp130 in solution. European Journal of Cell Biology, 2011, 90, 515-520.	1.6	4
510	Devic disease. Neurology, 2014, 82, 1294-1295.	1.5	4
511	The ADAM17 Metalloproteinase Maintains Arterial Elasticity. Thrombosis and Haemostasis, 2018, 118, 210-213.	1.8	4
512	Interleukin 6 Dependent Synaptic Plasticity in a Social Defeat-Susceptible Prefrontal Cortex Circuit. Neuroscience, 2019, 414, 280-296.	1.1	4
513	Brain-Restricted Inhibition of IL-6 Trans-Signaling Mildly Affects Metabolic Consequences of Maternal Obesity in Male Offspring. Nutrients, 2021, 13, 3735.	1.7	4
514	ADAM17: a potential therapeutic target for rheumatoid arthritis?. International Journal of Clinical Rheumatology, 2012, 7, 357-359.	0.3	3
515	ID: 207. Cytokine, 2015, 76, 102.	1.4	3
516	Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance. Cell Metabolism, 2016, 23, 563.	7.2	3
517	The balance between Treg and TH₁₇ cells: CD11b and interleukinâ€6. European Journal of Immunology, 2017, 47, 629-632.	1.6	3
518	Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. Oncotarget, 2016, 7, 55639-55648.	0.8	3
519	A Region within the Cytoplasmic Domain of the Interleukinâ€6 Signal Transducer gp130 Important for Ligandâ€induced Endocytosis of the ILâ€6 Receptor. Annals of the New York Academy of Sciences, 1995, 762, 410-412.	1.8	2
520	The Transcription Factor Repertoire of Flt3+ Hematopoietic Stem Cells. Cells Tissues Organs, 2008, 188, 103-115.	1.3	2
521	Intestinal inflammation is coordinated by the metalloprotease ADAM17. Cytokine, 2009, 48, 51.	1.4	2
522	Pharmaceutical Relevant Cytokine Receptors: Lessons from the First Drafts of the Human Proteome. Journal of Proteome Research, 2015, 14, 1330-1332.	1.8	2

#	Article	IF	Citations
523	Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine, 2020, 22, 100340.	3.2	2
524	Roles for ADAM17 in TNF-R1 Mediated Cell Death and Survival in Human U937 and Jurkat Cells. Cells, 2021, 10, 3100.	1.8	2
525	A NOVEL AND RAPID PREDICTION ASSAY FOR THE EFFECTIVENESS OF IL-6 RECEPTOR SPECIFIC ANTISENSE OLIGONUCLEOTIDES BY PROLIFERATION INHIBITION OF AN INTERLEUKIN-6 DEPENDENT CELL LINE. Cell Biology International, 2001, 25, 253-256.	1.4	1
526	Letter to the Editor:1H,15N and13C Backbone Assignment of the Carboxyl Terminal Domain of the Cytokine Binding Module of the Interleukin-6 Receptor. Journal of Biomolecular NMR, 2004, 29, 407-408.	1.6	1
527	New insights into the role and signalling processes of gp130. Arthritis Research and Therapy, 2011, 13, O10.	1.6	1
528	Natural soluble interleukin-15RÎ± is generated by cleavage that involves the tumor necrosis factor-Î±-converting enzyme (TACE/ADAM17).. Journal of Biological Chemistry, 2011, 286, 9894.	1.6	1
529	105. Cytokine, 2013, 63, 267-268.	1.4	1
530	Letter to the Editor: Non-specific effects resulting from use of tocilizumab in mice. Metabolism: Clinical and Experimental, 2020, 109, 154281.	1.5	1
531	Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice. Scientific Reports, 2021, 11, 3556.	1.6	1
532	Natural Glycoforms of Human Interleukin 6 Show Atypical Plasma Clearance. Angewandte Chemie, 2021, 133, 13492-13499.	1.6	1
533	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Journal of Cell Biology, 2010, 190, i2-i2.	2.3	1
534	SHEDDING OF THE INTERLEUKIN-6 RECEPTOR: MECHANISMS AND PHYSIOLOGICAL CONSEQUENCES. Biochemical Society Transactions, 1999, 27, A22-A22.	1.6	0
535	124 IL6/sIL6R-Transsignaling Controls Innate and Aquired Immunity. Cytokine, 2007, 39, 34.	1.4	0
536	149 Viral Interleukin-6 Transgenic Animals Display a Hyperplasic Spleen and Growth Retardation Phenotype. Cytokine, 2007, 39, 41.	1.4	0
537	ADAM17-mediated shedding of the IL-6R induces cleavage of the membrane stub by Î³-secretase. Cytokine, 2009, 48, 130-131.	1.4	0
538	PL1-3 IL-6 Trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. Cytokine, 2010, 52, 3.	1.4	0
539	SS2-5 Transgenic model with liver specific cell autonomous gp130 activation: Consequences for liver regeneration. Cytokine, 2010, 52, 14.	1.4	0
540	PL2-5 Human but not mouse IL-6R is a substrate for TACE: Analysis of the molecular basis of species specificity using chimeric IL-6R proteins. Cytokine, 2010, 52, 37.	1.4	0

#	Article	IF	Citations
541	PS2-17 Inflammatory reactions are orchestrated by the TNF-alpha-converting enzyme. Cytokine, 2010, 52, 53-54.	1.4	0
542	PL4-5 Blockade of IL-6 signaling via soluble IL-6R is superior to global IL-6 blockade by antibodies in models of inflammation and septic shock. Cytokine, 2010, 52, 100-101.	1.4	0
543	VEGFR2 Signaling in Intestinal Epithelial Cells Drives Development of Colitis-Associated Colon Cancer. Gastroenterology, 2011, 140, S-351.	0.6	0
544	Anti-TNF Antibodies Target T-Cell Apoptosis in Inflammatory Bowel Diseases via the mTNF/TNFR2 Signalling Pathway. Gastroenterology, 2011, 140, S-838.	0.6	0
545	PS1-051 The role of transsignaling in mediating interleukin-6 (IL-6) actions in the central nervous system (CNS). Cytokine, 2011, 56, 30.	1.4	0
546	121. Cytokine, 2013, 63, 271.	1.4	0
547	76. Cytokine, 2013, 63, 261.	1.4	0
548	Achieving specificity in the glial cell response to the gp130 cytokines. Journal of Neuroimmunology, 2014, 275, 142.	1.1	0
549	84. Cytokine, 2014, 70, 48.	1.4	0
550	161. Cytokine, 2014, 70, 67.	1.4	0
551	S-21. Cytokine, 2014, 70, 25.	1.4	0
552	ID: 88. Cytokine, 2015, 76, 81.	1.4	0
553	ID: 132. Cytokine, 2015, 76, 90-91.	1.4	0
554	ID: 122. Cytokine, 2015, 76, 88-89.	1.4	0
555	The Biology of Interleukin-6, a Major Target in Anti-Inflammatory Therapies. , 2016, , 476-484.		0
556	Proteolytic steps within signaling cascades make these signaling pathways irreversible. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2057-2058.	1.9	0
557	PS-046-Suppression of complex protumorigenic phenotypes in chronic injury-associated hepatocarcinogenesis is dependent on IL-6/STAT3 signaling. Journal of Hepatology, 2019, 70, e29.	1.8	0
558	FRI-297-Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha. Journal of Hepatology, 2019, 70, e526.	1.8	0

#	Article	IF	Citations
559	Editorial [Hot Topic: Screening for Proteins and Inhibitors (Guest Editor: Stefan Rose-John)]. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 115-115.	0.6	0
560	Meet the Guest Editor. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 205-205.	0.6	0
561	Cytokine Receptors. , 2005, , 39-52.		0
562	VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Journal of Cell Biology, 2010, 191, i12-i12.	2.3	0
563	IL6RA, Interleukin-6 Receptor Subunit Alpha. , 2016, , 1-5.		0
564	IL6RA, Interleukin-6 Receptor Subunit Alpha. , 2018, , 2565-2570.		0
565	Interleukin-6. , 2020, , 1-9.		0
566	Interleukin-6. , 2021, , 872-880.		0
567	Enhancement of proliferation of human umbilical cord bloodâ€“derived CD34+ hematopoietic stem cells by a combination of hyper-interleukin-6 and small molecules. Biochemistry and Biophysics Reports, 2022, 29, 101214.	0.7	0
568	IL-6 Responsiveness of CD4+ and CD8+ T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy. Journal of Clinical Medicine, 2022, 11, 2530.	1.0	0